Pharmaceutical Commerce

JULY 16, 2025

I'll explain why this "gold rush" is fraught with peril, from a risk management and insurance perspective. The elephant in the room: The critical absence of FDA approval The fundamental issue with compounded GLP-1s lies in their sidestepping of the rigorous FDA approval process.

Compounding

Pharmaceutical Commerce

JULY 23, 2025

Many companies have already been in the process of reshoring manufacturing to the United States to avoid the impending tariffs, including AstraZeneca, who plans to invest $50 billion by 2030 in US-based drug manufacturing and R&D, marking its largest single manufacturing investment globally.

Insurance Coverage and Processing

Pharmaceutical Commerce

JUNE 18, 2025

June 18th 2025 Article The June issue of Pharmaceutical Commerce highlights the importance of embracing agility—and adaptable strategies—to better navigate industry challenges. Click here to view our interactive June 2025 issue! Related Content The Art of Agility Mike Hennessy Jr.

Insurance Coverage and Processing

Pharmaceutical Commerce

JULY 1, 2025

1 There are specific diseases—including hemophilia and sickle cell disease (SCD)—that are more widespread in groups enrolled in Medicaid than commercially insured individuals, due to the program’s concentration on children, disabled adults, and those families financially impacted by treatment costs. of average manufacturer price.

Insurance Coverage and Processing

BioPharma Dive

JULY 31, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Vaccines Experts ousted from CDC panel warn of damage to US vaccine policy The 17 advisers fired last month by Robert F. vaccine policymaking process.” Kennedy Jr.

Vaccines

Putting Patients First Blog

SEPTEMBER 3, 2024

The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.

Drug Pricing

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). The NHC provides the following comments to CMS to improve on the steps it has already taken to date.

Drug Pricing

Pharmaceutical Commerce

JUNE 13, 2025

Bill Roth Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drug prices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone.

Insurance Coverage and Processing

Proxsys Rx

AUGUST 16, 2023

In the past week, no less than three articles have called attention to the restrictions drug manufacturers have imposed to evade their legal responsibility to honor 340B program prescription discounts — as well as the impact those restrictions have had on 340B-eligible nonprofit entities’ ability to serve their patients and communities.

Insurance Coverage and Processing